SCHEMBL1335150

SCHEMBL1335150

CCOC(=O)c1cnn(-c2ccccn2)c1C(F)(F)F

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 9/20 0.69
NPC1 O15118 2/20 0.69
RAB9A P51151 2/20 0.69
TP53 P04637 1/20 0.69
ALDH1A1 P00352 10/20 0.58
KDM4E B2RXH2 8/20 0.58
MAPT P10636 6/20 0.58
L3MBTL1 Q9Y468 4/20 0.58
GAA P10253 4/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
TDP1 Q9NUW8 1/20 0.58
GUCY1A1 Q02108 2/20 0.56
GUCY1B1 Q02153 2/20 0.56
PTGS2 P35354 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.55
POLB P06746 1/20 0.55
TRPC1 P48995 2/20 0.53
TRPC3 Q13507 2/20 0.53
STIM1 Q13586 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30147756 1.00 HPGD (0.69) HPGDNPC1RAB9ATP53ALDH1A1
SCHEMBL18134659 0.90 HPGD (0.65) HPGDNPC1RAB9ATP53ALDH1A1
SCHEMBL2941393 0.85 HPGD (0.56) HPGDNPC1RAB9ATP53ALDH1A1
SCHEMBL2854006 0.85 NPC1 (0.54) HPGDNPC1RAB9ATP53ALDH1A1
SCHEMBL31252558 0.85 MAPT (0.54) HPGDNPC1RAB9ATP53ALDH1A1
SCHEMBL31252563 0.85 GUCY1A1 (0.55) HPGDNPC1RAB9ATP53ALDH1A1
SCHEMBL26123370 0.85 GUCY1A1 (0.55) HPGDNPC1RAB9ATP53ALDH1A1
SCHEMBL26126954 0.85 MAPT (0.54) HPGDNPC1RAB9ATP53ALDH1A1
SCHEMBL21604832 0.85 MAPT (0.51) HPGDNPC1RAB9ATP53ALDH1A1
SCHEMBL18134666 0.84 HPGD (0.67) HPGDNPC1RAB9ATP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4707276-A2 MALT1 MODULATORS AND USES THEREOF Rarefied Biosciences, Inc. (US) 2026-03-11 EP disclosed
EP-4499611-B1 MALT1 MODULATORS AND USES THEREOF RAREFIED BIOSCIENCES INC (US) 2026-02-18 EP disclosed
EP-4673150-A2 COMPOSITIONS AND METHODS FOR TREATING MALT1 ASSOCIATED DISEASES Rarefied Biosciences, Inc. (US) 2026-01-07 EP disclosed
US-20250326738-A1 MALT1 Modulators and Uses Thereof RAREFIED BIOSCIENCES, INC. (US) 2025-10-23 US disclosed
EP-4499611-A1 MALT1 MODULATORS AND USES THEREOF Rarefied Biosciences, Inc. (US) 2025-02-05 EP disclosed
WO-2024182599-A2 COMPOSITIONS AND METHODS FOR TREATING MALT1 ASSOCIATED DISEASES RAREFIED BIOSCIENCES, INC. (US) 2024-09-06 WO disclosed
EP-3807266-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-25 EP disclosed
EP-3807266-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-25 EP disclosed
WO-2023192506-A1 MALT1 MODULATORS AND USES THEREOF RARIFIED BIOSCIENCES, INC. (US) 2023-10-05 WO disclosed
CN-112585128-B Pyrazole derivatives as MALT1 inhibitors 詹森药业有限公司 2023-02-21 CN disclosed
WO-2019243964-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed
US-8389509-B2 Substituted pyrazole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2013-03-05 US disclosed
US-8389509-B2 Substituted pyrazole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2013-03-05 US disclosed
US-8389509-B2 Substituted pyrazole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2013-03-05 US disclosed
EP-2382211-B1 PYRAZOLE-I, 2, 4 -OXAD IAZOLE DERIVATIVES AS S.PHING0SINE-1-PH0SPHATE AGONISTS BRISTOL MYERS SQUIBB CO (US) 2012-12-19 EP disclosed
US-20110275610-A1 SUBSTITUTED PYRAZOLE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2011-11-10 US disclosed
US-20110275610-A1 SUBSTITUTED PYRAZOLE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2011-11-10 US disclosed
US-20110275610-A1 SUBSTITUTED PYRAZOLE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2011-11-10 US disclosed
EP-2382211-A1 PYRAZOLE-I, 2, 4 -OXAD IAZOLE DERIVATIVES AS S.PHING0SINE-1-PH0SPHATE AGONISTS Bristol-Myers Squibb Company (US) 2011-11-02 EP disclosed
WO-2010085584-A1 PYRAZOLE-I, 2, 4 -OXAD IAZOLE DERIVATIVES AS S.PHING0SINE-1-PH0SPHATE AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275610-A1 SUBSTITUTED PYRAZOLE COMPOUNDS S1PR3, S1PR1, S1PR4 HPGD 2466/4885NPC1 479/4885RAB9A 1343/4885
US-20250326738-A1 MALT1 Modulators and Uses Thereof MALT1, SQSTM1, PPP1R10 HPGD 3460/4885NPC1 1239/4885RAB9A 1099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.